Irish Journal of Medical Science (1971 -)

, Volume 186, Issue 3, pp 565–570 | Cite as

Optic neuritis secondary to antiandrogen therapy

Case based reviews
First Online:
Received:
Accepted:

Abstract

Background

Optic neuropathy is a disorder characterised by dysfunction or destruction of the optic nerve tissues. Acquired causes include interruption in the blood supply, nutritional deficiency, compression by a tumour or aneurysm, trauma, and toxic types (Ambizas and Patel In US Pharm 36(4):HS2–HS6, 1). Drug-induced optic neuropathy is of the toxic type and can be defined as a clinical syndrome characterised by papillomacular bundle damage, central, or cecocentral scotoma, and reduced colour vision (Ambizas and Patel In US Pharm 36(4):HS2–HS6, 2011; Sharma and Sharma In Indian J Ophthalmol 59(2):137–141, 2).

Aim

To report a case unilateral optic neuritis, secondary to the use of the antiandrogen, cyproterone acetate.

Case report

A 21-year-old female presented with a 4-day history of right brow pain exacerbated by eye movement, and blurring of the right temporal field of vision. She had been taking desogestrel 75 mg and cyproterone acetate 50 mg for the previous 2 months for hormone imbalance. Unaided right visual acuity measured 6/9 and unaided left visual acuity measured 6/6 on Snellen chart. Right red desaturation was present. Goldmann perimetry showed a right enlarged blind spot with predominantly temporal visual field loss. Visually evoked potential (VEP) testing of the right eye showed slightly increased latency, but normal amplitude. Three weeks after discontinuation of the antiandrogen therapy, her symptoms resolved. Repeat Goldmann visual fields showed expansion.

Conclusion

Known side-effects of cyproterone acetate include retinal vascular disorder and retinal vein thrombosis, but an association with optic neuritis had not been described to date. There was a temporal relationship between cessation of the medication and improvement in visual symptoms. This implies that discontinuation of the offending drug constitutes the basis of treatment in drug-induced optic neuropathy.

Keywords

Optic neuritis Antiandrogen Polycystic ovarian syndrome Endocrinology Ophthalmology 
This is a preview of subscription content, log in to check access.

Notes

Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

  1. 1.
    Ambizas EM, Patel PN (2011) Drug-induced optic neuropathy. US Pharm 36(4):HS2–HS6Google Scholar
  2. 2.
    Sharma P, Sharma R (2011) Toxic optic neuropathy. Indian J Ophthalmol 59(2):137–141CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Al-Dhibi H, Chaudhry IA, Al-Saati A, Shamsi FA (2007) Efficacy of intravitreal triamcinolone for macular oedema due to CRVO after anti-androgen therapy for hirsutism in a young monocular female. Br J Ophthalmol 91(11):1564–1565CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Markus H, Polkey M, Harrison M (1992) Visual loss and optic atrophy associated with cyproterone acetate. BMJ 305(6846):159CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Aroudj S, Baratta A (2012) Paraphilia, chemical castration and optic neuropathy: a case report. Ann Medico–Psychol 170:579–581 (no. 8) Google Scholar
  6. 6.
    Bove et al (2014) Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler 20(12):1584–1592CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Maggio et al (2005) The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest 28:116–119CrossRefPubMedGoogle Scholar
  8. 8.
    Trufyn JJ et al. ( 2013) The role of oral contraceptives in optic neuritis: the story behind the study, initial experiences, and lessons learned. A thesis submitted to the faculty of graduate studies in partial fulfillment of the requirements for the degree of master of science. Department of neuroscience, Calgary, AlbertaGoogle Scholar
  9. 9.
    Confavreux C, Aimard G, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103:281–300CrossRefPubMedGoogle Scholar
  10. 10.
    Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernán MA (2005) Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 62:1362–1365CrossRefPubMedGoogle Scholar
  11. 11.
    Bove R et al (2016) Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler 22(7):935–943CrossRefPubMedGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2016

Authors and Affiliations

  1. 1.Mater Misericordiae University HospitalDublinIreland

Personalised recommendations